Foghorn Therapeutics Inc. FHTX 深 滬
交易中 12-12 10:03:20 美东时间
4.4885
+0.009
+0.19%
華盛通- 最 高4.545
- 今 開4.53
- 成交量 3216股
- 最 低 4.479
- 昨 收 4.48
- 總市值 2.54亿
- 52周最高 6.7899
- 市盈率 靜 --
- 換手率 0.01%
- 52周最低 2.9448
- 委 比 85.63%
- 總股本 5655.13万
- 歷史最高 28.265
- 量 比 0.57
- 振 幅 1.47%
- 歷史最低 2.70
- 每 手 1
- 風險率 0.64%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Platform Technologies Drive $211B Surge in Precision Cancer Treatment
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Dec. 11, 2025 /PRNewswire/ -- Equity Insider News Commentary – November's wave of FDA oncology approvals signals the industry's shift to...
12-11 23:17
美股大行评级 | 潜在涨幅218.88%！Kyverna Therapeutics获摩根士丹利升目标价至25美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持Kyverna Therapeutics"超配"评级，目标价从20美元升至25美元；Maxim Group：维持Capricor Therapeutics"买入"评级，目标价从25美元升至50美元
12-05 08:35
Stifel Initiates Coverage On Foghorn Therapeutics with Buy Rating, Announces Price Target of $12
Stifel analyst Laura Prendergast initiates coverage on Foghorn Therapeutics (NASDAQ:FHTX) with a Buy rating and announces Price Target of $12.
12-05 00:56
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
<p><p>CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the 8<sup>th</sup> Annual Evercore Healthcare Conference, being held December 2-4, 2025, in Coral Gables, FL. With an initial focus in oncology, Foghorn’s...
11-25 12:00
4D Molecular Therapeutics taps Kristian Humer as CFO
4D Molecular Therapeutics (FDMT) has appointed Kristian Humer as chief financial officer. Humer is a seasoned finance executive and biotechnology leader with more than two decades of experience, inclu...
11-17 19:17
4DMT Appoints Kristian Humer as Chief Financial Officer
4D Molecular Therapeutics任命Kristian Humer为首席财务官，负责财务策略和运营。Humer在金融和生物技术领域拥有超过20年的经验，曾担任Citi的医疗投资银行业务负责人，并担任多家公开上市公司 CFO。此次任命正值公司推进多个III期临床项目及准备商业化之际。公司CEO David Kirn表示，Humer的专业背景将助力4DMT实现长期增长和价值最大化。Humer表示期待与团队合作，推动公司的财务和战略发展。
11-17 11:00
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
Foghorn Therapeutics Unveils Strategic Advancements with Lilly
Foghorn Therapeutics ( ($FHTX) ) has issued an announcement. In November 2025, ...
11-08 05:59
Foghorn Therapeutics Q3 EPS $(0.25) Beats $(0.30) Estimate, Sales $8.153M Beat $6.197M Estimate
Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.30) by 17.76 percent. This is a 19.35 percent increase over losses of $(0.31) per share
11-05 20:14
